Paris and Tarrytown, NY, September 27, 2024. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance...

Paris and Tarrytown, NY, September 27, 2024. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance...

TUESDAY, Oct. 1, 2024 -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with...

The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the expanded...

With this approval, JNJ's Rybrevant is now approved for a total of four indications in the United States.

RAHWAY, N.J.--(BUSINESS WIRE) September 18, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S....

Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.

The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first approval for the given...

PRINCETON, N.J.--(BUSINESS WIRE)--26 September 2024-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration...

The US FDA has approved Bristol Myers Squibb’s oral medicine, Cobenfy, for treating schizophrenia in adults. This is the first new type of...